

RenuTend (--)- Suspension for injection

Authorised

- Tesrivetcel

Product identification

Medicine name:

RenuTend (--)- Suspension for injection

Active substance:

Tesrivetcel

Target species:

Horse

Route of administration:

Intralesional use

Product details

Active substance and strength:

Tesrivetcel

Presentation_strength:2.0-3.5 x 10⁶ Reference:Hse Index:0

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:**Intralesional use:**

-

Horse

- Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QM09AX90

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

France

Package description:

Packaging:Vial (COC), Package_size:1 vial, Content:1 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:

19/04/2022

Manufacturing sites for batch release:

Global Stem cell Technology

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

19/04/2022

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 7/09/2023

[Download](#)

ema-puar-renutend-v-005428-par-en.pdf